Tesaro drops after Zejula pricing, competing PARPi trial miss

The shares of drug maker Tesaro are falling with two possible headwinds cited by analysts as the potential culprit, namely the pricing of its niraparib treatment and the disappointing trial results of another drug in the same therapeutic space.